In fact, a dual COX-2/5-LOX inhibitor, licofelone (ML3000) [33,34], has been successfully completed phase III trials and is demonstrated to be superior in safety and equally efficacious for standard treatments of osteoarthritis. The gene discussed is PTGS2; the disease is osteoarthritis.